1. Home
  2. ASMB vs HSPO Comparison

ASMB vs HSPO Comparison

Compare ASMB & HSPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • HSPO
  • Stock Information
  • Founded
  • ASMB 2005
  • HSPO 2014
  • Country
  • ASMB United States
  • HSPO United States
  • Employees
  • ASMB N/A
  • HSPO N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • HSPO Blank Checks
  • Sector
  • ASMB Health Care
  • HSPO Finance
  • Exchange
  • ASMB Nasdaq
  • HSPO Nasdaq
  • Market Cap
  • ASMB 84.5M
  • HSPO 92.0M
  • IPO Year
  • ASMB 2010
  • HSPO 2022
  • Fundamental
  • Price
  • ASMB $13.02
  • HSPO $11.70
  • Analyst Decision
  • ASMB Buy
  • HSPO
  • Analyst Count
  • ASMB 2
  • HSPO 0
  • Target Price
  • ASMB $35.00
  • HSPO N/A
  • AVG Volume (30 Days)
  • ASMB 20.5K
  • HSPO 3.5K
  • Earning Date
  • ASMB 03-27-2025
  • HSPO 01-01-0001
  • Dividend Yield
  • ASMB N/A
  • HSPO N/A
  • EPS Growth
  • ASMB N/A
  • HSPO 2.63
  • EPS
  • ASMB N/A
  • HSPO 0.28
  • Revenue
  • ASMB $28,326,000.00
  • HSPO N/A
  • Revenue This Year
  • ASMB $282.16
  • HSPO N/A
  • Revenue Next Year
  • ASMB N/A
  • HSPO N/A
  • P/E Ratio
  • ASMB N/A
  • HSPO $41.53
  • Revenue Growth
  • ASMB N/A
  • HSPO N/A
  • 52 Week Low
  • ASMB $11.03
  • HSPO $10.80
  • 52 Week High
  • ASMB $19.93
  • HSPO $12.41
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 40.89
  • HSPO 52.06
  • Support Level
  • ASMB $12.10
  • HSPO $11.70
  • Resistance Level
  • ASMB $14.25
  • HSPO $11.89
  • Average True Range (ATR)
  • ASMB 0.60
  • HSPO 0.10
  • MACD
  • ASMB -0.10
  • HSPO -0.01
  • Stochastic Oscillator
  • ASMB 35.11
  • HSPO 18.37

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

Share on Social Networks: